Oncogenes, cancer and imaging

Journal of Nuclear Medicine

Volumn 40, Issue 3, 1999, Pages 498-504

  Urbain, Jean Luc ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Molecular probes; Oncogenes; Tumor suppressor genes

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; GENE MUTATION; HUMAN; IMAGING; MOLECULAR PROBE; NONHUMAN; NUCLEIC ACID PROBE; ONCOGENE; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES;

EID: 0033021315     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Urbain JL, Shore K, Vekemans MC, et al. Scintigraphic imaging of oncogenes with untisense probes: does it make sense? Eur J Nucl Med. 1994:22:499-504.
2. Kraus MH, Popeseu NC, Amsbaugh SC. King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987: 6:605-610.
3. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M. et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-11-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994:35:1054-1063.
4. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science. 1993;261:1004-1012.
5. Uhlmann E. Peyman A. Oligonucleolide analogs containing dephospho-internucleoside linkages. Methods Mol Biol 1993:20:355-389.
6. Zhao Q, Matson S, Herrera CJ. Eisher E. Yu H, Krieg AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorotioate, and mixed phosphorotioate and methlyphosphonate oligonucleolides. Antisense Res Dev. 1993;3:53-66.
7. Agrawal S, Temsamani J, Galhrailh W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmakinetics 1995;28:7-16.
8. Crooke RM. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti Cancer Drug Design. 1991;6:609-646.
9. Galbraith WM, Hohson WC. Giclas PC, Schechter PJ. Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorotioate oligonucleotides in the monkey. Antisense Res Dev. 1994;4:201-206.
10. 99mTc-labeled oligonucleotides. Q J Nucl Med. 1996;40:202-208.
11. Manoharan M, Johnson LK, McGee DPC, et al. Chemical modifications to improve uptake and bioavailability of antisense oligonucleotides. Ann NY Acad Sci. 1992:660:306-309.
12. Rose DJ. Characterization of antisense binding properties of peptide nucleic acids by capillary gel electrophoresis. Analytical Chem. 1993:65:3545-3549.
13. Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, Egholm M, Hnatowich DJ. In vitro hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med. 1997:38:907-913.
14. 125I MRK-16 monoclonal antibody. Nucl Med Biol. 1995:22:497-504.
15. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1996:36:1825-1835.
16. Goldenherg DM, Larson SM, Reisfeld RA, Schlom J. Targeting cancer with radiolabeled antibodies, Immunol Today. 1995;16:261-264.
17. Katoh Y, Nakata K, Kohno K. et al. Immunoscintigraphy of human tumors transplanted in nude mice with radiolabeled anti-ras p21 monoclonal antibodies. J Nucl Med. 1990: 31:1520-1526.
18. Adel Bakir A, Eccles SA, Bubich JW. et al. c-erbB-2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med. 1990:33:2154-2161.
19. Dean CA, Eccles SA, Valeri M, et al. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. Cell Biophys. 1993;22:111-127.
20. HFR2 monoclonal antibody has antiproliterative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989:9:1165-1172.
21. Bacus SS, Stancovski I, Huberman E, et al. Tumor-inhibitory monoclonal antibody to the HER-2/neu receptor induce differentiation of human breast cancer cells Cancer Res. 1992:52:2580-2589.
22. Ohnishi Y, Nakamura H, Yoshimura M. et al Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br J Cancer. 1995:71:969-973.
23. Valone FH, Kaufman, PA. Guyre PM. et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematotherapy: 1995:4:471-475.
24. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2BI, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother. 1995:4:453-456.
25. Smellie WJ, Dean CJ. Sacks NP, et al. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p 185: comparison of iodogen and N-succinimidyl-4-methyl-3-(tri-n-butylstanyl) benzoate radiodination methods. Cancer Res. 1995:55:5842-5846.
26. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039-3051.
27. Clauss MA, Jain RK, Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res, 1990;50:3487-3492.
28. Hand PH, Nuti M. Colcher D, Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal amibodies to tumor-associated antigens. Cancer Res. 1983;43:728-735.
29. Lind P, Lechner P. Haussman B. Development of human antimouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunocol Radiopharm. 1991;4:811-818.
30. Adams GP, McCartnev JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993;53:4026-4034.
31. Deshane J, Loechel F. Conry RM, Siegal GP. King CR. Curiel DT. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1994;1:332-337.
32. Tai MS, McCartney JE, Adams GP, et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res. 1995;55:5983S-5989S.
33. Kern JA, Torney L, W'einer D. Gazdar A. Shepard HM, Fendly B. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Resp Cell Mol Biol. 1993;9:448-154.
34. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255-263.
35. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumourdevelopment in vivo hy downregulation of the p 185 neu receptor. Nature Med. 1995; 1:644-648.
36. Dougall WC, Greene MI. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Cell Biophys. 1994;24-25:209-218.
37. HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol. 1993;229:969-995.
38. Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabeled peptide from complementarity-determining region of antitumor antibody. Lancet. 1995;346:1662-1666.
39. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science. 1990;249:386-390.
40. Scott JK, Craig L. Random peptide libraries. Curr Opin Biotechnol. 1994:5: 40-48.
41. Doorbar J, Winter G. Isolation of a peptide antagonist to the thromhin receptor using phage display. J Mol Biol. 1994;244:361-369.
42. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996:380:364-366.
43. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Biochemistry. 1994;91:7129-7133.
44. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the α5βI integrin from phage display library. J Biol Chem. 1993;268:20205-20210.
45. McLafferty MA. Kent RB. Ladner RC. Markland W. M 13 bacteriophage displaying disulfide-constrained microproteins. Gene. 1993:128:29-36.
46. Delforge D, Art M. Gillon B. Delaive E. Raes M. Remacle J. Automated solid-phase synthesis of cyclic peptides bearing a side chain tail designed for subsequent chemical grafting. Analytical Kittchan. 1996;242:180-186.
47. Sheldon K, Liu D, Ferguson J, Gariepy J. Loligomers design of de novo peptide-based intracellular vehicles. Proc Natl Acad Sci USA. 1995;92:2056-2060.
48. Mannironi C, DiNardo A, Kruscoloni P, Tocchini-Valentini GP. In vitro selection of dopamine RNA ligands. Biochemistry. 1997;36:9726-9734.
49. Lin Y. Jayasena SD. Inhibition of multiple thermostable DNA polymerase by a heterodimeric aptamer. J Mol Biol. 1997;271:100-111.
50. Urvil PT, Kakiuchi N. Zhou DM, Shimotohno K, Kumar PK.,Nishikawa S. Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. Eur J Biochem. 1997;248:130-138.
51. Eaton BE, Gold L, Hicke BJ, Janjic N, Jucker FM, Sebesta DP. Post-SELEX combinatorial optimization of aptamers. Bioorg Med Chem. 1997;5:1087-1096.